Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Gastrointestinal 2Sarcoma 1Myeloid 1Head & Neck 1Gynecologic 1Genitourinary 1Classical hematology 1CNS 1Breast 1

Conditions

Thrombocytopenia 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Azacitidine 41Cytarabine 27fludarabine phosphate 25Cyclophosphamide 23venetoclax 21fludarabine 21Peripheral Blood Stem Cell Transplantation 20Mycophenolic Acid 17Filgrastim 17Decitabine 17Tacrolimus 16Whole-Body Irradiation 15ruxolitinib 14Cyclosporine 14Busulfan 14Melphalan 12Methotrexate 10Imatinib Mesylate 10Stem Cell Transplantation 9Antilymphocyte Serum 8Alemtuzumab 8nilotinib 7decitabine and cedazuridine drug combination 7Granulocyte Colony-Stimulating Factor 7Rituximab 6Injections 6Idarubicin 6Dasatinib 6Clofarabine 6AP 1903 reagent 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Microarray Analysis × Myeloid × Clear all
NCT01165996 2019-03-04

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Case Comprehensive Cancer Center

Phase 1/2 Completed
25 enrolled 13 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Thrombocytopenia, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡